Neuroblastoma
A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51)
Subtype terms (2)
More specific conditions that are subtypes of Neuroblastoma in the MeSH hierarchy.
- Esthesioneuroblastoma, Olfactory
7 drugs (5 approved, 2 experimental)
- Ganglioneuroblastoma
24 drugs (21 approved, 3 experimental)
Drugs by status
Approved for this indication (7)
Phase 4 trials (2)
Phase 3 trials (37)
- aldesleukin
- fluorodopa
- capmatinib
- calcium phosphate
- corticorelin ovine triflutate
- cisplatin
- 18f-mfbg
- dacarbazine
- 125-iodine
- cyclophosphamide
- 131 i-omburtamab
- vincristine
- vindesine
- ifosfamide
- thiotepa
- topotecan
- dexrazoxane
- stem cells
- bone autograft
- prednisone
- urea
- doxorubicin
- sodium thiosulfate
- etoposide
- melphalan
- mesna
- immune globulin (human)
- alectinib
- rituximab
- carboplatin
- +7 more
Phase 2 trials (154)
- hu14.18k322a
- cabozantinib
- naltrexone
- il-7
- lorvotuzumab mertansine
- ga-68-dota-toc
- tenatumomab
- autologous halk.car t cells
- tacrolimus
- ensartinib
- imatinib
- vinblastine
- oxaliplatin
- cetuximab
- voriconazole
- tgfβi nk cells
- genistein
- olaparib
- gefitinib
- mycophenolate
- idasanutlin
- bevacizumab
- tumor-pulsed dendritic cells
- gd2bi-aatc
- perfosfamide
- anti-cd30 bispecific antibody-armed anti-cd3-activated autologous t-cells (cd30 biab-aatc)
- autologous natural killer cells
- retinoic acid
- crizotinib
- bvd-523
- +124 more
Phase 1 trials (109)
- tolcapone
- tamoxifen
- o6-benzylguanine
- decitabine
- 1rg-cart
- sorafenib
- 7-hydroxystaurosporine
- enoblituzumab
- interleukin-12
- interferon gamma-1b
- keyhole limpet hemocyanin
- 4-1bbζ egfr806-egfrt
- vandetanib
- carmustine
- simvastatin
- anti-flt3 car-t
- varicella zoster virus glycoprotein e antigen
- everolimus
- gene-modified tumor cell vaccine therapy
- lorlatinib
- ketoconazole
- ir-101
- 14g2a.zeta chimeric receptor transduced autologous ebv specific cytotoxic t-lymphocytes
- autologous cd133+ stem cells
- i15.nkg2d.zeta nk cells
- autologous dendritic cells loaded with autologous tumor lysate
- ss2017
- autologous CD276 car-T cells
- 2-o, 3-o desulfated heparin
- cefepime
- +79 more
Organizations
Organization Involved with Phase 4 Indications (11)
Organization Involved with Phase 3 Indications (32)
- National Cancer Institute (NCI)
- Children's Cancer and Leukaemia Group
- Duke University
- Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany
- Newcastle University
- Oregon Health and Science University
- St. Anna Kinderkrebsforschung
- Stanford University
- Sheffield Hallam University
- University of Glasgow
- University of Leeds
- University of Leicester
- University of Michigan
- University of Southern California
- University of Alberta
- Wayne State University
- Yale University
- Societe Internationale d'Oncologie Pediatrique (SIOP)
- University of Calgary
- University of Cincinnati
- University of Cologne
- Vancouver Coastal Health
- Royal Marsden Hospital NHS Trust
- Curie Institute
- Institut Gustave Roussy
- University of Texas at Houston
- University of Alabama, Birmingham
- Mercy Regional Cancer Center at Mercy Medical Center
- University of Western Australia
- Moorgreen Hospital, Southampton
- +2 more
Organization Involved with Phase 2 Indications (104)
- Molecular Insight Pharmaceuticals
- Spectrum Pharmaceuticals
- Celgene
- Advanced Accelerator Applications
- Roche
- AstraZeneca
- Eli Lilly
- Genentech
- Genzyme
- Sanofi
- Novartis
- Bayer
- BioInvent International AB
- Cancer Prevention Pharmaceuticals, Inc.
- Cortice Biosciences, Inc.
- Jubilant DraxImage Inc.
- Laboratorio Elea S.A.C.I.F. y A.
- Oncurious NV
- Fundació Sant Joan de Déu
- National Institutes of Health (NIH)
- National Cancer Institute, France
- National Center for Research Resources (NCRR)
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Bambino Gesù Hospital and Research Institute
- Baylor University
- Burzynski Research Institute
- Case Western Reserve University
- Cancer Research UK
- +74 more
Organization Involved with Phase 1 Indications (60)
- AbbVie
- Foundation Medicine
- Millennium Pharmaceuticals
- Merck
- Curis
- Pfizer
- Geron Corporation
- MacroGenics
- NantWorks
- SignalRX Pharmaceuticals, Inc.
- National Heart, Lung, and Blood Institute (NHLBI)
- Children's Hospital of Philadelphia
- Canadian Cancer Trials Group
- Emory University
- Herbert Irving Comprehensive Cancer Center
- Indiana University
- Lund University
- New York Medical College
- Pediatric Brain Tumor Consortium
- Shenzhen Institute for Innovation and Translational Medicine
- Texas Tech University
- University of Louisville
- University of Rochester
- University of South Florida
- University of Toronto
- Wake Forest University
- Mayo Clinic
- South Plains Oncology Consortium
- St. Louis University
- University of California, San Diego
- +30 more
Organization Involved with Other Experimental Indications (11)